BASEL, SWITZERLAND--(Marketwire - October 06, 2011) -
Basilea Pharmaceutica AG /
Basilea receives request for extraordinary shareholders meeting to elect
additional members to the board of directors
Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
Basel, Switzerland, October 6, 2011 - Basilea Pharmaceutica Ltd. (SWISS: BSLN)
announced today that it has received a request to hold an extraordinary
Basilea has received a request from its shareholder HBM BioVentures (Cayman)
Ltd., which holds more than 15% of Basilea's shares, to convene an
shareholders meeting and expand the current five member board. HBM indicated
commitment to a long-term effort and a close relationship with Basilea's
existing board. HBM proposes to nominate for election as additional members to
the board of directors Dr. Thomas Werner, Dr. Seng Chin Mah, Dr. Thomas M.
Rinderknecht and a fourth candidate yet to be named.
Basilea's board of directors will evaluate the request, set the date and the
agenda of the meeting and publish the invitation in due course. Basilea
anticipates that the meeting will take place at around the end of November.
Basilea Pharmaceutica Ltd. is headquartered in Basel, Switzerland, and listed
the SIX Swiss Exchange (SWISS: BSLN). Basilea Pharmaceutica International
fully integrated research and development operations are focused on
antifungals and oncology drugs, as well as on the development of dermatology
drugs, targeting the medical challenge of resistance and non-response to
treatment options in the hospital and specialty care setting.
Basilea is currently marketing Toctino® (alitretinoin), the only approved
treatment for adults with severe chronic hand eczema unresponsive to potent
topical corticosteroids, in Denmark, Finland, France, Germany, Norway,
Switzerland and the United Kingdom and has appointed distributors for
in other selected European markets, Canada, Israel, Mexico and the Republic of
Korea. A phase III clinical program on alitretinoin for the treatment of
chronic hand eczema is ongoing in the U.S.
For its phase III compound isavuconazole, a potential best-in-class azole
antifungal for the treatment of life-threatening invasive fungal infections,
company has entered into a license, co-development and co-promotion agreement
with Astellas Pharma Inc.
In addition, Basilea is developing ceftobiprole, a late-stage novel anti-MRSA
(methicillin-resistant Staphylococcus aureus) broad-spectrum cephalosporin
antibiotic, for the first-line treatment of potentially life-threatening
resistant bacterial infections. Ceftobiprole has a broad coverage of both
positive bacteria, including MRSA, and many clinically important Gram-negative
bacteria such as Pseudomonas spp.
Basilea's BAL30072, a novel antibiotic for the treatment of resistant Gram-
negative infections, and the oncology drug BAL101553 for the treatment of
resistant cancers are in phase I clinical testing.
This communication expressly or implicitly contains certain forward-looking
statements concerning Basilea Pharmaceutica Ltd. and its business. Such
statements involve certain known and unknown risks, uncertainties and other
factors, which could cause the actual results, financial condition,
or achievements of Basilea Pharmaceutica Ltd. to be materially different from
any future results, performance or achievements expressed or implied by such
forward-looking statements. Basilea Pharmaceutica Ltd. is providing this
communication as of this date and does not undertake to update any
forward-looking statements contained herein as a result of new information,
events or otherwise.
This press release can be downloaded from www.basilea.com.
--- End of Message ---
Basilea Pharmaceutica AG
P.O Box Basel Switzerland
Listed: Freiverkehr in Börse Stuttgart,
Freiverkehr in Börse Berlin,
Open Market (Freiverkehr) in Frankfurter Wertpapierbörse,
Freiverkehr in Bayerische Börse München;
Press release (PDF):
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Basilea Pharmaceutica AG via Thomson Reuters ONE